- Home
- FSUN vs SPRY Comparison
FSUN vs SPRY Comparison
Compare FSUN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSUN
- SPRY
- Stock Information
- Founded
- FSUN 1892
- SPRY 2015
- Country
- FSUN United States
- SPRY United States
- Employees
- FSUN N/A
- SPRY N/A
- Industry
- FSUN Major Banks
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- FSUN Finance
- SPRY Health Care
- Exchange
- FSUN Nasdaq
- SPRY Nasdaq
- Market Cap
- FSUN 1.0B
- SPRY 1.6B
- IPO Year
- FSUN N/A
- SPRY N/A
- Fundamental
- Price
- FSUN $39.05
- SPRY $15.07
- Analyst Decision
- FSUN Hold
- SPRY Strong Buy
- Analyst Count
- FSUN 1
- SPRY 4
- Target Price
- FSUN N/A
- SPRY $24.00
- AVG Volume (30 Days)
- FSUN 22.8K
- SPRY 842.1K
- Earning Date
- FSUN 01-01-0001
- SPRY 11-11-2024
- Dividend Yield
- FSUN N/A
- SPRY N/A
- EPS Growth
- FSUN N/A
- SPRY N/A
- EPS
- FSUN 3.05
- SPRY N/A
- Revenue
- FSUN $348,035,000.00
- SPRY $500,000.00
- Revenue This Year
- FSUN N/A
- SPRY $14,206.67
- Revenue Next Year
- FSUN $79.99
- SPRY $1,212.02
- P/E Ratio
- FSUN $13.16
- SPRY N/A
- Revenue Growth
- FSUN N/A
- SPRY 128.31
- 52 Week Low
- FSUN $29.51
- SPRY $3.38
- 52 Week High
- FSUN $43.80
- SPRY $17.08
- Technical
- Relative Strength Index (RSI)
- FSUN 18.80
- SPRY 52.61
- Support Level
- FSUN $38.79
- SPRY $14.59
- Resistance Level
- FSUN $40.80
- SPRY $17.08
- Average True Range (ATR)
- FSUN 0.57
- SPRY 0.85
- MACD
- FSUN -0.07
- SPRY -0.15
- Stochastic Oscillator
- FSUN 34.04
- SPRY 40.51
About FSUN FirstSun Capital Bancorp
Firstsun Capital Bancorp is the financial holding company for Sunflower Bank, National Association. It provides a full range of deposit, lending, treasury management, wealth management and online banking products and services. The company operates in two segments - Banking operations and Mortgage operations, out of which the majority of the revenue is generated from the Banking operations segment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.